epocrates logo
epocrates logo
epocrates logo
  • 0

Journal Article Synopsis

JACI

AAAAI 2025: Omalizumab outperforms oral immunotherapy in multi-food allergy treatment

March 4, 2025

card-image

Omalizumab may be a viable alternative to oral immunotherapy (OIT) for treating multi-food allergies, particularly for patients who experience severe reactions to OIT, according to findings presented at the American Academy of Allergy, Asthma & Immunology (AAAAI)/World Allergy Organization (WAO) Joint Congress in San Diego, CA.

Study details: Stage 2 of the OUtMATCH trial directly compared omalizumab with OIT for the first time. At 10 U.S. locations, 177 children and adolescents (ages 1-17) and three adults (ages 18-55) with confirmed allergies to less than half a peanut and ≥2 other common foods were enrolled. After the first stage, 117 participants received 8 weeks of omalizumab injections. They were then randomized into 2 groups: Group A received omalizumab and multi-allergen OIT for eight weeks, followed by placebo injections and OIT for 44 weeks; Group B received omalizumab and placebo OIT for 8 weeks, followed by omalizumab and placebo OIT for 44 weeks.

Results: Omalizumab was more effective than OIT for treating multi-food allergies in patients with low initial tolerance. By the end of treatment, 36% of participants on omalizumab tolerated ≥2 grams of peanut protein and 2 other allergens, compared with 19% on OIT (odds ratio, 2.6; P = 0.031). Omalizumab also showed superiority for success with ≥2 foods (P = 0.004) and other secondary endpoints. No differences were found in the per-protocol analysis. Serious adverse events, treatment discontinuations, and epinephrine-treated events were more common in the OIT group.

Sources:

Wood, R., et al. (2025, February). The Journal of Allergy and Clinical Immunology. Treatment of Multi-Food Allergy with Omalizumab Compared to Omalizumab-Facilitated Multi-Allergen OIT. https://www.jacionline.org/article/S0091-6749(24)02309-1/fulltext

(2025, March 3). NIH. Omalizumab treats multi-food allergy better than oral immunotherapy. https://www.nih.gov/news-events/news-releases/omalizumab-treats-multi-food-allergy-better-oral-immunotherapy

Trending icon

TRENDING THIS WEEK

EPOCRATES CME

View Catalog

view all CME activities
learn more about epocrates plus
Clinical FAQ icon

Clinical FAQs

Check out the answers to frequently asked questions about our clinical content.

Download Epocrates from the App StoreDownload Epocrates from the Play Store
About UsFeaturesBusiness SolutionsHelp & Feedback
© 2026 epocrates, Inc.   Terms of UsePrivacy PolicyEditorial PolicyDo Not Sell or Share My Information